From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
LU117 should be started 6 weeks before initiating Docetaxel (Taxotere) treatment. The most recent and highest quality study, published in 2024 in The Lancet. Oncology 1, evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 before docetaxel treatment in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer. The study found that [177Lu]Lu-PSMA-617 followed by docetaxel improved antitumour activity in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased toxic effects. The treatment regimen involved administering two cycles of [177Lu]Lu-PSMA-617 7·5 GBq every 6 weeks intravenously, followed 6 weeks later by six cycles of docetaxel 75 mg/m2 every 3 weeks intravenously.
Key points to consider:
- The study demonstrated the safety and efficacy of [177Lu]Lu-PSMA-617 before docetaxel treatment in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer.
- The treatment regimen involved a 6-week interval between [177Lu]Lu-PSMA-617 and docetaxel treatment.
- The study found that [177Lu]Lu-PSMA-617 followed by docetaxel improved antitumour activity without increased toxic effects.
- The most common grade 3 or 4 treatment-related adverse events were febrile neutropenia and diarrhoea, which were similar in both treatment groups.
Overall, the evidence suggests that starting LU117 6 weeks before initiating Docetaxel (Taxotere) treatment is a safe and effective approach for patients with de-novo high-volume metastatic hormone-sensitive prostate cancer, as supported by the study published in The Lancet. Oncology 1.